Evangelos michelakis biography of christopher

          Christopher W White currently works at the Division of Cardiac Surgery, University of Alberta....

          Evangelos D Michelakis, Christopher J Porter, Miguel A Andrade-Navarro Background: The cause of pulmonary arterial hypertension (PAH) was.

        1. Evangelos D Michelakis, Christopher J Porter, Miguel A Andrade-Navarro Background: The cause of pulmonary arterial hypertension (PAH) was.
        2. Evangelos Michelakis published promising results in January showing it significantly shrunk tumours in rats.
        3. Christopher W White currently works at the Division of Cardiac Surgery, University of Alberta.
        4. Evangelos Michelakis, the Alberta cardiologist who is spearheading DCA research: We continue to be moved by your sustained interest and.
        5. Evangelos Michelakis, Canada.

          6. New Possibility for Brain Tumour Treatment


          University of Alberta researchers are using an unpatented drug to change the metabolism of cancer cells, giving new hope to patients with some of the deadliest forms of brain cancer.

          The research team, led by Dr.

          Evangelos Michelakis, a professor in the department of medicine, tested dichloroacetate (DCA) on five patients with advanced forms of brain cancer. The team found that tumours in four of five patients either regressed, or stopped growing.

          Dr.

          Michelakis says the study “doesn’t lend any strong evidence to say that the drug is safe or efficacious.” Michelakis says, instead, that the study was meant to show a new mechanism for treating tumours – by targeting the tumours’ metabolism.

          DCA is a water-soluble powder that is taken orally.

          It can change the metabolism of gliobastoma brain tumour cells, which Dr. Michelakis describes as “one of the deadliest forms of cancer.” Though the study was not designed to show DCA is a cure for c